Differential prognostic value of residual nodal burden in breast cancer subtypes.

Autor: Thai CHNC; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA., An SJ; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA., Haase CR; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA., Selfridge JM; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Agala CB; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.; Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA., Spanheimer PM; Department of Surgery, University of North Carolina, Chapel Hill, NC, USA. Philip_Spanheimer@med.unc.edu.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Philip_Spanheimer@med.unc.edu.; Department of Genetics, University of North Carolina at Chapel Hill, 170 Manning Drive, Physicians Office Building Suite 1150, Chapel Hill, NC, 27599-7213, USA. Philip_Spanheimer@med.unc.edu.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Sep 15. Date of Electronic Publication: 2024 Sep 15.
DOI: 10.1007/s10549-024-07494-5
Abstrakt: Purpose: Residual cancer burden (RCB) index after neoadjuvant chemotherapy (NAC) is highly prognostic in patients with breast cancer (BC) but does not account for subtype or the precise impact of residual nodal burden (RNB). We aimed to precisely define the effect of RNB on survival by subtypes.
Methods: Adult women with non-metastatic BC diagnosed from 2006 to 2021 in the National Cancer Database (NCDB) who received NAC followed by surgery within 8 months were included. RNB was also evaluated as a predictor of mortality with multivariable logistic regression. Kaplan-Meier analyses were performed to compare overall survival.
Results: 51,917 patients were included. After adjustment, ypN stage was the strongest predictor of mortality, with an odds ratio (OR) of 2.24 (95% CI 2.08-2.41) for ypN1 vs ypN0 and increased with increasing nodal burden-ypN2 vs ypN0 OR 5.03, 95% CI 4.60-5.51 and ypN3 vs ypN0 OR 8.85, 95% CI 7.88-9.93. Stratification of survival curves with higher RNB is most pronounced for triple-negative breast cancer (TNBC) with an absolute difference of 64% in 5-year overall survival between ypN0 and ypN3 patients, and lowest for the ER+/HER2- subtype with a 25% absolute difference in 5-year OS between ypN0 and ypN3 patients. On interaction analysis, ypN status was a stronger predictor of mortality for the TNBC subtype compared to other subtypes.
Conclusion: RNB has a significantly different impact on survival by BC subtypes. Future study of optimal therapeutic strategies for patients with residual nodal disease after NAC should account for subtype-specific differences in prognosis.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: